Zoetis (ZTS) Capital Expenditures (2012 - 2026)
Zoetis' (ZTS) quarterly Capital Expenditures came in at $110.0 million in Q1 2026, down 38.2% year-on-year from $178.0 million in Q1 2025, and down 82.2% on a QoQ basis from $618.0 million in Q4 2025.
Zoetis (ZTS) Capital Expenditures (2012 - 2026) Analysis & Trends
Zoetis (ZTS) has 15 years of Capital Expenditures data on file, last reported at $110.0 million in Q1 2026.
- On a quarterly basis, Capital Expenditures fell 38.2% year-over-year to $110.0 million in Q1 2026; TTM through Mar 2026 was $553.0 million, a 1248.78% increase from a year earlier, with the FY2025 full-year figure at $621.0 million, up 20600.0% from the prior year.
- Capital Expenditures for Q1 2026 stood at $110.0 million, down from $618.0 million in the prior quarter.
- Over the last five years, Capital Expenditures for ZTS reached as high as $618.0 million in Q4 2025 and fell as low as -$385.0 million in Q3 2023.
- Historically, Capital Expenditures has averaged $82.6 million across 5 years, with a median of $3.5 million in 2022.
- On a YoY basis, Capital Expenditures climbed as much as 61900.0% in 2025 and fell as far as 32500.0% in 2025.
- Year by year, Capital Expenditures stood at $581.0 million in 2022, then sank by 100.34% to -$2.0 million in 2023, then soared by 50.0% to -$1.0 million in 2024, then soared by 61900.0% to $618.0 million in 2025, then plunged by 82.2% to $110.0 million in 2026.
- Per Business Quant data, the three most recent Capital Expenditures figures were $110.0 million in Q1 2026, $618.0 million in Q4 2025, and -$324.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 168.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 110.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.95 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 99.60 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 39.90 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 51.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 10.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 110.00 Mn |
| Mar 31, 2026 | 110.00 Mn |
| Dec 31, 2025 | 618.00 Mn |
| Dec 31, 2025 | 618.00 Mn |
| Sep 30, 2025 | -324.00 Mn |
| Sep 30, 2025 | -324.00 Mn |
| Jun 30, 2025 | 149.00 Mn |
| Jun 30, 2025 | 149.00 Mn |
| Mar 31, 2025 | 178.00 Mn |
| Mar 31, 2025 | 178.00 Mn |
| Dec 31, 2024 | -1.00 Mn |
| Dec 31, 2024 | -1.00 Mn |
| Sep 30, 2024 | 1.00 Mn |
| Sep 30, 2024 | 1.00 Mn |
| Jun 30, 2024 | -137.00 Mn |
| Jun 30, 2024 | -137.00 Mn |
| Mar 31, 2024 | 140.00 Mn |
| Mar 31, 2024 | 140.00 Mn |
| Dec 31, 2023 | -2.00 Mn |
| Dec 31, 2023 | -2.00 Mn |